Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rhone-Poulenc Rorer

Executive Summary

Company will pay over $1 mil. to the Canadian government under a "voluntary compliance undertaking" resulting from a December 1991-July 1992 investigation by the Canadian Patented Medicine Prices Review board of the price of the nonbenzodiazepine hypnotic Imovane. RPR surrendered patent rights to Imovane in Canada in July 1992. The company said it is not developing the product for the U.S.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022828

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel